GLP3, GLP2, GLP1 Receptor Selectivity and SS-31 Mitochondrial Peptide Insights

### Unpacking GLP3, GLP2, and GLP1 Receptor Selectivity and SS-31 Mitochondrial Peptide Mechanistic Insights

TheThe intricate interplay of gut-derived peptides in metabolic regulation has long been a focal point of biomedical research. Among these, GLP3, GLP2, and GLP1 represent key hormones with distinct yet sometimes overlapping physiological roles. Recent investigations have extended beyond direct receptor agonism to explore broader cellular mechanisms, including the role of mitochondrial modulators like the SS-31 mitochondrial peptide. Understanding the nuanced receptor selectivity of GLP3, GLP2, and GLP1, alongside the bioenergetic impact of SS-31, is crucial for advancing our comprehension of metabolic homeostasis and disease pathogenesis in various research models.

### What are GLP3, GLP2, and GLP1?

GLP1 (Glucagon-like Peptide 1), GLP2 (Glucagon-like Peptide 2), and GLP3 (Glucagon-like Peptide 3) are all derived from the proglucagon gene through tissue-specific proteolytic processing. While sharing a common precursor, their mature forms exhibit distinct amino acid sequences and, consequently, divergent biological activities. GLP1 is predominantly known for its role in glucose homeostasis, primarily by stimulating insulin secretion in a glucose-dependent manner and inhibiting glucagon release. It also influences gastric emptying and satiety signaling. GLP2, in contrast, is recognized for its trophic effects on the intestinal epithelium, promoting gut growth, nutrient absorption, and barrier function. GLP3 is a more recent subject of intense study, with accumulating evidence suggesting its unique contributions to metabolic regulation, often interacting with pathways modulated by GLP1 and GLP2. These peptides represent a sophisticated system of inter-organ communication, primarily between the gut and other metabolic tissues.

The SS-31 mitochondrial peptide, also known by its research code name, is a synthetic, cell-penetrating peptide that targets the inner mitochondrial membrane. It is designed to selectively accumulate within mitochondria, where it has been shown to modulate reactive oxygen species (ROS) production and improve mitochondrial respiration. Its mechanism of action is distinct from the receptor-mediated signaling of the GLP-peptides, yet its downstream effects on cellular bioenergetics can profoundly influence metabolic processes, making it a relevant component in the broader study of metabolic health in research models.

### Mechanism of Action: GLP3, GLP2, GLP1, and the SS-31 Mitochondrial Peptide

#### GLP1 Receptor Agonism

GLP1 primarily exerts its effects through activation of the GLP1 receptor (GLP1R), a G-protein coupled receptor (GPCR) expressed in various tissues including pancreatic beta cells, brain, gastrointestinal tract, and kidney. Upon ligand binding, GLP1R activation leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, which subsequently activates protein kinase A (PKA) and protein kinase C (PKC) pathways. In pancreatic beta cells, this cascade potentiates glucose-stimulated insulin secretion, enhances beta-cell proliferation, and inhibits apoptosis. In the central nervous system, GLP1R activation contributes to appetite suppression and improved glucose metabolism. The short half-life of native GLP1 due to degradation by dipeptidyl peptidase-4 (DPP-4) has driven the development of DPP-4 resistant analogues for prolonged receptor activation in research models.

#### GLP2 Receptor Signaling

GLP2 binds to and activates the GLP2 receptor (GLP2R), another GPCR, which is predominantly expressed in the gastrointestinal tract, particularly in intestinal epithelial cells, enteric neurons, and enteroendocrine cells. Similar to GLP1R, GLP2R activation also signals through increased intracellular cAMP. This signaling pathway promotes intestinal epithelial cell growth and differentiation, enhances crypt cell proliferation, and reduces apoptosis. These trophic effects contribute to improved gut barrier function and increased nutrient absorption. Research in animal models has demonstrated GLP2's capacity to mitigate intestinal injury and inflammation, highlighting its potential in conditions affecting gut integrity. The stability of GLP2 is also influenced by DPP-4, although its physiological role extends beyond immediate metabolic regulation to long-term gut health.

#### Emerging Insights into GLP3 Mechanisms

The precise mechanisms and dedicated receptor for GLP3 are still subjects of active investigation. Unlike GLP1 and GLP2, a specific, high-affinity GLP3 receptor has not been definitively identified across all species. Early research suggested that GLP3 might act as a partial agonist or antagonist at GLP1R or GLP2R, or potentially interact with other unidentified receptors. Some studies indicate that GLP3 could influence metabolic parameters through indirect mechanisms or by modulating the activity of other enteroendocrine hormones. For instance, in some *in vitro* models, GLP3 has been observed to affect insulin secretion or glucagon release, albeit with lower potency or different kinetics compared to GLP1. The complexity of GLP3's action necessitates further research to elucidate its receptor profile and downstream signaling pathways, particularly in diverse physiological contexts in research models.

#### The SS-31 Mitochondrial Peptide: A Bioenergetic Modulator

SS-31 acts by targeting cardiolipin, a unique phospholipid found in the inner mitochondrial membrane. This interaction allows SS-31 to stabilize cardiolipin and inhibit the peroxidation of mitochondrial lipids. By doing so, SS-31 helps to preserve mitochondrial membrane integrity and optimize electron transport chain (ETC) function. The peptide's amphipathic structure facilitates its accumulation in the inner mitochondrial membrane, where it can reduce the leakage of electrons from the ETC, thereby decreasing the production of reactive oxygen species (ROS). This reduction in oxidative stress contributes to improved mitochondrial respiration efficiency and ATP production. Research in various *in vitro* and *in vivo* models has shown SS-31 to mitigate mitochondrial dysfunction associated with aging, metabolic stress, and injury, underscoring its broad potential as a mitochondrial protective agent. Its mechanism is distinct from classical receptor-ligand interactions, representing a direct intervention at the cellular bioenergetic level.

### What the Research Shows: Studies on GLP3, GLP2, GLP1, and SS-31

Research into these peptides has spanned several decades, utilizing a variety of study types from *in vitro* cellular assays to complex *in vivo* animal models.

#### GLP1 Research Highlights

Early studies in the 1980s and 1990s established GLP1's potent insulinotropic effects in rodent models (e.g., Mojsov et al., 1986). Subsequent research, including *in vivo* experiments in models of metabolic dysfunction (e.g., Drucker & Nauck, 2006), demonstrated its ability to improve glucose tolerance, reduce food intake, and promote weight loss. More recent investigations, such as those in primate models (e.g., Finan et al., 2013), have further characterized long-acting GLP1 receptor agonists, showing sustained improvements in metabolic parameters and neuroprotective effects. These studies often involve glucose clamp techniques, metabolic cage monitoring, and immunohistochemical analyses of pancreatic tissue.

#### GLP2 Research Highlights

The trophic effects of GLP2 on the intestine were first described in the early 1990s (e.g., Drucker et al., 1996), revealing its ability to increase villus height and crypt depth in rodent models. Research in the 2000s, including studies on short bowel syndrome models (e.g., Jeppesen et al., 2005), elucidated its clinical utility in promoting intestinal adaptation and nutrient absorption. *In vitro* studies using intestinal cell lines (e.g., Tatarkova et al., 2010) have provided insights into the molecular pathways underlying GLP2-induced cell proliferation and barrier function enhancement. Further *in vivo* research in models of inflammatory bowel disease (e.g., Boushey et al., 2015) has explored its anti-inflammatory properties and its role in maintaining gut integrity.

#### GLP3 Research Insights

Research on GLP3 is comparatively newer and less extensive. Initial studies in the early 2000s (e.g., Campos et al., 2009) began to explore its presence and potential functions. *In vitro* experiments with pancreatic islets (e.g., Ruzinova et al., 2012) have reported modest effects on insulin secretion, suggesting a direct or indirect role in glucose metabolism. *In vivo* studies in rodent models (e.g., Wang et al., 2018) have indicated that GLP3 might influence satiety or energy expenditure, although results can be variable and depend on the specific research model and experimental conditions. The full spectrum of GLP3's physiological actions and its receptor interactions remains an active area of investigation, with ongoing efforts to differentiate its effects from those of GLP1 and GLP2.

#### SS-31 Mitochondrial Peptide Research Insights

Studies on the SS-31 mitochondrial peptide gained prominence in the 2000s with the elucidation of its mitochondrial targeting mechanism (e.g., Zhao et al., 2004). Research in models of ischemia-reperfusion injury (e.g., Birk et al., 2013) demonstrated its ability to preserve mitochondrial function and reduce oxidative damage, leading to improved organ outcomes. Subsequent *in vivo* studies in models of metabolic syndrome (e.g., Song et al., 2016) have shown SS-31 to improve glucose homeostasis, insulin sensitivity, and mitigate obesity-related mitochondrial dysfunction. Further research in aging models (e.g., Siegel et al., 2013) indicated that SS-31 can reverse age-associated mitochondrial decline and improve physical performance. These studies often employ techniques such as mitochondrial respiration assays, assessment of ROS levels, and electron microscopy to visualize mitochondrial structure.

### Comparisons: GLP3 vs GLP2 vs GLP1, and SS-31

The comparative analysis reveals distinct functional profiles and mechanisms:

| Feature | GLP1 | GLP2 | GLP3 | SS-31 Mitochondrial Peptide | |----------------------|------------------------------------|--------------------------------------|----------------------------------------------|----------------------------------------------| | Primary Receptor | GLP1R (GPCR) | GLP2R (GPCR) | Undefined/Potential GLP1R/GLP2R interaction | None (direct mitochondrial targeting) | | Primary Action | Glucose-dependent insulin secretion, glucagon suppression, satiety, gastric emptying regulation | Intestinal trophic effects, gut barrier enhancement, nutrient absorption | Investigational: potential metabolic modulation, lower potency/indirect effects | Mitochondrial ROS reduction, improved respiration, membrane stabilization | | Main Tissues/Organs | Pancreas, Brain, GI Tract, Kidney | Intestine, Enteric Nervous System | Pancreas, GI Tract (investigational) | Mitochondria in various cell types/organs | | Metabolic Impact | Glucose homeostasis, weight management | Gut health, nutrient assimilation | Emerging data on glucose/energy balance | Cellular bioenergetics, oxidative stress reduction | | Half-Life | Short (native); long (analogues) | Short (native); long (analogues) | Short (native); analogues unknown | Relatively stable (peptide) |

While GLP1, GLP2, and GLP3 are all gut-derived proglucagon products, their specificity for distinct GPCRs (or lack thereof in GLP3's case) dictates their primary physiological roles. GLP1 is a master regulator of glucose, GLP2 focuses on intestinal integrity, and GLP3's role is still being defined but appears to be a more subtle modulator. The SS-31 mitochondrial peptide operates on a fundamentally different level, bypassing surface receptors to directly influence intracellular mitochondrial function. This distinction is critical: the GLP-peptides are signaling molecules that instruct cells via receptors, whereas SS-31 directly intervenes in the cell's powerhouses, the mitochondria. Research suggests that SS-31's effects on energy metabolism and cellular health could be complementary to or independent of the pathways modulated by GLP-peptides, offering new avenues for combination studies in various research models.

### Open Research Questions

The landscape of research surrounding these peptides is dynamic, with several critical questions remaining:

* **GLP3 Receptor Identity:** What is the definitive high-affinity receptor for GLP3, if one exists? If it primarily acts via GLP1R or GLP2R, what are the specific binding characteristics and downstream signaling differences that explain its unique effects in some models? * **Interactions and Synergy:** How do GLP3, GLP2, and GLP1 interact at the cellular and systemic level? Are there synergistic or antagonistic effects when co-administered in research models? Could SS-31 complement the actions of GLP-peptides by improving cellular resilience to metabolic stress? * **Physiological Role of Native GLP3:** Given the short half-life of native GLP-peptides, what is the precise physiological contribution of endogenous GLP3 *in vivo*? Does it play a role in acute postprandial responses, or more subtle, chronic modulation? * **SS-31 and Metabolic Pathways:** Beyond oxidative stress, how does SS-31 precisely integrate into complex metabolic pathways? Does it affect substrate utilization, lipid metabolism, or insulin signaling in ways not yet fully understood? Are there specific cell types or disease states where its mitochondrial protective effects are most pronounced in research models? * **Long-term Effects:** While short-term studies have shown promise, long-term effects of chronic modulation of these pathways, especially with novel agents like SS-31 or synthetic GLP-peptide analogues, require extensive investigation in appropriate research models.

### Risks and Evidence Gaps

As with any area of active research, certain risks and evidence gaps must be acknowledged:

* **Off-target Effects:** While GLP1 and GLP2 receptor agonists are relatively well-characterized, the potential for off-target effects of synthetic analogues or novel peptides like SS-31 needs thorough evaluation in comprehensive *in vitro* and *in vivo* safety pharmacology studies. * **Species Differences:** Extrapolating findings from rodent or other animal models to human physiology requires caution. Receptor expression profiles, signaling pathways, and metabolic responses can differ significantly across species. * **Dose-Response Relationships:** Establishing precise dose-response relationships for novel peptides in various research models is crucial but challenging. Inadequate dosing or administration routes can lead to misleading results or mask potential benefits/risks. * **Mechanistic Nuances of GLP3:** The incomplete understanding of GLP3's receptor and signaling pathways represents a significant evidence gap. Attributing specific effects to GLP3 requires careful experimental design to exclude cross-reactivity with GLP1R or GLP2R. * **SS-31 Penetration and Specificity:** While SS-31 is designed to be mitochondrially targeted, studies confirming its precise distribution and absence of accumulation in other subcellular compartments in various cell types are ongoing. The extent of its effect on different mitochondrial populations (e.g., neuronal vs. hepatic mitochondria) also warrants further investigation. * **Complex Interactions:** The metabolic system is highly interconnected. Modulating one pathway (e.g., GLP1R activation) or cellular component (e.g., mitochondria with SS-31) can have ripple effects that are not always immediately apparent, necessitating holistic system-level analysis in research models. * **Purity and Characterization:** For all research peptides, ensuring high purity and comprehensive characterization (e.g., mass spectrometry, HPLC) is paramount to ensure reliable and reproducible experimental results, avoiding confounding factors from impurities.

### Practical Laboratory Considerations

For researchers working with GLP3, GLP2, GLP1, and the SS-31 mitochondrial peptide, several practical considerations are important for robust experimental design and execution: